Business Wire07.30.21
Medical imaging, robotics, and AI technology company, Promaxo Inc. (Promaxo) has hired Srirama Venkataraman, Ph.D., who joins the company as vice president of Clinical Research & Strategy. With a mission to improve lives through state of the art medical technology, Promaxo recently received the 510(k) clearance from the U.S. Food and Drug Administration for its innovational MRI platform.
“Sri's experience launching commercially successful products such as UroNav in the prostate biopsy market, is invaluable for Promaxo's growth trajectory as we continue to expand clinical indications for Promaxo’s MR platform,” said Dr. Amit Vohra, founder and CEO of Promaxo. “As an established and experienced executive, Sri will play an integral role in helping to advance Promaxo’s clinical footprint and success in the commercial space.”
Dr. Venkataraman brings more than two decades of experience, having previously worked with highly respected organizations, such as Fox Chase Cancer Center, Mayo Clinic, Philips, and Stryker, developing and executing clinical programs including novel MR imaging applications. The tech pioneer will lead Promaxo’s clinical development initiatives focused on establishing clinical research partnerships, clinical programs, and advancing novel applications. Venkataraman has developed and managed programs in breast and prostate cancer, cardiac and cardiovascular imaging, neurological and metabolic disease. He earned a doctorate degree in physics from Michigan Technological University and an MBA from Rutgers Business School.
“My passion is to push the boundaries with innovative healthcare technologies to improve patient outcomes,” said Dr. Venkataraman. “I’m thrilled to work with the team at Promaxo towards creating a patient-centric system with design, effectiveness and precision at its forefront.”
With a growing body of clinical data and strong IP protection, Promaxo is poised to manage the entire in-office care continuum. Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, Calif., and backed by over 60 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient screening and interventions. The company has formed numerous long-term and strategic partnerships with investor groups as it enters the U.S. market.
“Sri's experience launching commercially successful products such as UroNav in the prostate biopsy market, is invaluable for Promaxo's growth trajectory as we continue to expand clinical indications for Promaxo’s MR platform,” said Dr. Amit Vohra, founder and CEO of Promaxo. “As an established and experienced executive, Sri will play an integral role in helping to advance Promaxo’s clinical footprint and success in the commercial space.”
Dr. Venkataraman brings more than two decades of experience, having previously worked with highly respected organizations, such as Fox Chase Cancer Center, Mayo Clinic, Philips, and Stryker, developing and executing clinical programs including novel MR imaging applications. The tech pioneer will lead Promaxo’s clinical development initiatives focused on establishing clinical research partnerships, clinical programs, and advancing novel applications. Venkataraman has developed and managed programs in breast and prostate cancer, cardiac and cardiovascular imaging, neurological and metabolic disease. He earned a doctorate degree in physics from Michigan Technological University and an MBA from Rutgers Business School.
“My passion is to push the boundaries with innovative healthcare technologies to improve patient outcomes,” said Dr. Venkataraman. “I’m thrilled to work with the team at Promaxo towards creating a patient-centric system with design, effectiveness and precision at its forefront.”
With a growing body of clinical data and strong IP protection, Promaxo is poised to manage the entire in-office care continuum. Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, Calif., and backed by over 60 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient screening and interventions. The company has formed numerous long-term and strategic partnerships with investor groups as it enters the U.S. market.
